Gipogonadizm u muzhchin
- Autores: Manusharova R.A1, Cherkezova E.I1
-
Afiliações:
- Edição: Nº 12 (2014)
- Páginas: 61-69
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287155
- ID: 287155
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The article presents the results of treatment, as well as diagnosis and differential diagnosis of male hypogonadism. The analysis of current approaches to the treatment of hypogonadism was performed. It is shown that the main goal of treatment of the disease is hormone replacement therapy with testosterone. Growth hormone preparation or domestic drug somatotropin are used in case of low body height, if the growth zones are open. The use of drugs stimulating growth leads to an increase of body height by 10 to 12 cm. Defects of descent of testis should be corrected at an early age.
Texto integral
Bibliografia
- Josso N., Boussin L., Knebelmann B., et al. Antimullerian Hormone and intersex state. Trends Endocrinol. Metabol. 1991; 2(227): 227-33.
- Lee M.M., Donahoe P.K., Silverman B.L., et al. Measurements of serum Mullerian inhibiting substance in the evaluation of children with nonpalpable gonads. N. Engl. J. Med. 1997; 336: 1480-86.
- Abramsky L., Chappie J. (Klinefelter syndrome) and 47,XYY: estimated rates of and indication for postnatal diagnosis with imblications for prenatal counseling. Prenat. Diagn. 1997; 17: 363-68.
- Propping P. Psychiatrische Genetik. Springer, Berlin Heidelberg New York. 307-15.
- Mechede D., Horst J. Neue Erkenntnisse zur Genetik des Kallmann-syndroms Und des Idiopathischen Hypogonadotropen Hypogonadiismus. Geburtsh Frauenheilkd. 1999; 59: 381-85.
- Waldstreicher J., Seminara S.B., Jameson J.L., et al. The genetic and clinical heterogeneity of gonadotropin-releasing hormone deficiency in the human. J. Clin. Endocrinol. Metab. 1996; 81: 4388-95.
- Мазо Е.Б., Гамидов С.И., Иремашвили В.В. Современные аспекты этиологии, патогенеза, диагностики и лечения гипогонадизма у мужчин. Медицинские новости. 2007; 3: 28-32.
- Манушарова Р.А., Черкезова Э.И. Лечение мужского гипогонадизма препаратами тестостерона. РМЖ 2006; 26: 1932-35.
- Манушарова Р.А., Потемкин В.В., Черкезова Э.И. Первичный и вторичный гипогонадизм у мужчин патогенез, клиника, лечение. Эндокринология / Под ред. В.В. Потемкина. 2013. С. 620-95.
- Hauffa B.P. One-year results of growth hormone treatment of short stature in Prader-Willi syndrome. Acta Paeiatr. 1997; 423(Suppl): 63-5.
- Jeffcoate W.J., Laurance B.M., Edwards C.R.W., et al. Endocrine function in the Prader-Willi syndrome. Clin. Endocrinol 1980; 12: 81-9.
- Cassidy S.B. Prader-Will syndrome J. Med. Genet. 1997; 34: 917-23.
- Jamieson on C.R., van der Burgt J.L., Brady A.F., et al. Mapping gene for Noonan syndrome to the long arm of chromosome 12. Nat. Genet 1994; 8: 357-60.
- Elsawi M.M., Pryor J.P., Klufio G., et al. Genital tract function in men with Noonan Syndrome. Med. Genet.1994; 31: 468-70.
- Chang B., Borer J.G., Tan P.E., et al. Large-cell calcifying Sertoli cell tumor of the testis: case report and review of the literature. Urology. 1998; 520-23.
- Эндокринология (руководство для врачей) / Под ред. В.В. Потемкина. 2013. C. 667-82.
- Эндокринология (руководство для врачей). Под ред. В.В. Потемкина. 2013. C. 546-618.
- Aiman J. Griffin J.E. The frequency of androgen receptor deficiencyin in fertile men. J. Clin Endocrinol. Metab. 1982; 54: 725-32.
- Bowers S.P., Pearlman N.W., Mccintyre R.C. Jr, et al. Cost-effective Management of gynecomastia. Am. J. Surg.1998; 176: 638-41.
Arquivos suplementares
